BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

PHI-financial-stockholm-pitch

PHI presents at Financial Stockholm

Watch CEO Anders Månsson present the Company and its future plans at the Financial Stockholm investor meeting on December 11th, 2024.
Anders-Mansson-PHI-241209-1046

BioStock: PHI:s vd kommenterar företrädesemissionen

PHI genomför just nu en fullt ut garanterad företrädesemission om cirka 64 Mkr som avslutas den 20 december. För att berätta mer om hur likviden avses användas, samt om satsningarna för att öka den globala försäljningen, besökte bolagets vd Anders Månsson BioStocks studio.
fill or kill podcast

PHI som gäst i Fill or Kill podcast: Avsnitt 506

Lyssna på Fill or Kill intervjun med PHI vd Anders Månsson. Avsnitt 506 – Äntligen lite nya case.
PHI-at-Aktieportfoljen-Live

PHI presents at Aktieportföljen Live

Watch CEO Anders Månsson present the Company and its future plans at Aktieportföljen Live.
1234…10

Latest News

Phase Holographic Imaging Announces Next Generation HoloMonitor

Phase Holographic Imaging (PHI) is pleased to announce that the next generation of PHI’s live cell imaging system enters its final development stage. The new model is currently undergoing pre-production testing both internally and externally at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine.
Phase Holographic Imaging logotype

Phase Holographic Imaging Announces Management Changes

Recent technical progress has led the Board of Directors of Phase Holographic Imaging (PHI) to decide to focus resources on the company’s clinical product development program. In relation to this, the Board of Directors has, in discussion with CEO Anders Månsson, decided to initiate the search for a new CEO to lead the ambitious development that lies ahead.

PHI announces last day of trading in BTA

See All News